dihexa factory API | CAS 1401708-83-5 Manufacturer & Supplier in China dihexa clinical trials status Dihexa

10.1038/3311 Nat

Increased energy Enhanced performance Reduce weight & fat Embrace the simplicity no need for injections

As observed in disease models of gastroparesis (Tseng et al., 2022), chronic constipation (Wang et al., 2023), functional dyspepsia (Tait and Sayuk, 2021), and irritable bowel syndrome (IBS) (Mayer et al., 2023), there is a notable loss of enteric neurons and ICCs, along with a reduction in the size and quantity of ganglia, underscoring the critical role of the ENS in maintaining GI function and motility

Multiple sclerosis, a condition that can affect the brain and spinal cord, can also be managed with this formulation